AAV Capsid Engineering for NPC1 Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective treatments, prevention, and potential cures for Niemann-Pick Disease Type C (NPC1), a neurodegenerative disorder characterized by cholesterol accumulation, as current therapies are inadequate.
Innovation Solution
Development of recombinant adeno-associated virus (AAV) vectors that evade neutralizing antibodies and selectively target tissues, carrying a nucleic acid with a transfer cassette encoding the NPC1 protein to treat, prevent, or cure NPC1, utilizing specific capsid protein subunits and sequences to enhance transduction efficiency and tissue specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neutralizing antibodies are present in the host, then immune response is activated, but transduction efficiency decreases
Solution Approach 1:
The patent modifies the capsid protein sequence parameters by introducing amino acid substitutions at specific positions (e.g., positions 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100) to create variants that evade neutralizing antibodies while preserving transduction efficiency. This parameter change approach allows the vector to adapt to immune pressure without sacrificing its core function.
2Manufacturing precision
If tissue specificity is enhanced to target specific organs, then therapeutic precision improves, but vector design complexity increases
Solution Approach 1:
The patent achieves tissue specificity by making localized modifications to the capsid protein structure at specific regions (N-terminal, C-terminal, or internal domains) rather than redesigning the entire vector. This allows different capsid variants to be created for targeting different tissues (liver, brain, heart, muscle) by modifying only the relevant local regions of the capsid protein.
Solution Approach 2:
The capsid protein is divided into functional segments (VP1, VP2, VP3 with distinct domains) that can be independently modified. This segmentation allows researchers to target specific regions for tissue tropism optimization without affecting other critical functions of the capsid.
3Productivity
If transduction efficiency is increased to deliver more therapeutic cargo, then treatment effectiveness improves, but immune recognition increases
Solution Approach 1:
The patent uses systematic parameter changes in the capsid protein sequence to create variants with altered immune recognition profiles. By changing specific amino acid residues that are epitopes for neutralizing antibodies, the vectors can achieve high transduction efficiency while evading immune detection and neutralization.
Data Source
AI summary
Provided herein are gene therapy compositions and methods for treating, preventing, and/or curing NPC1. More specifically, the disclosure provides Adeno-associated virus (AAV) vectors for delivery of nucleic acids and nucleic acids (including AAV transfer cassettes) for treating, preventing, and/or curing NPC1.